A detailed history of Commonwealth Equity Services, LLC transactions in Adc Therapeutics Sa stock. As of the latest transaction made, Commonwealth Equity Services, LLC holds 40,413 shares of ADCT stock, worth $82,038. This represents 0.0% of its overall portfolio holdings.

Number of Shares
40,413
Previous 32,600 23.97%
Holding current value
$82,038
Previous $103,000 23.3%
% of portfolio
0.0%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 18, 2024

BUY
$2.59 - $4.01 $20,235 - $31,330
7,813 Added 23.97%
40,413 $127,000
Q2 2024

Jul 31, 2024

BUY
$2.55 - $5.09 $35,146 - $70,155
13,783 Added 73.25%
32,600 $103,000
Q1 2024

Apr 29, 2024

SELL
$1.66 - $5.29 $1,718 - $5,475
-1,035 Reduced 5.21%
18,817 $84,000
Q4 2023

Feb 06, 2024

BUY
$0.47 - $1.79 $9,330 - $35,535
19,852 New
19,852 $33,000
Q1 2023

May 11, 2023

BUY
$1.92 - $5.45 $19,378 - $55,006
10,093 New
10,093 $19,000

Others Institutions Holding ADCT

About ADC Therapeutics SA


  • Ticker ADCT
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 77,645,296
  • Market Cap $158M
  • Description
  • ADC Therapeutics SA, a commercial-stage biotechnology company, develops antibody drug conjugates (ADC) for patients suffering from hematological malignancies and solid tumors. Its flagship product ZYNLONTA that is in Phase II clinical trial for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma;...
More about ADCT
Track This Portfolio

Track Commonwealth Equity Services, LLC Portfolio

Follow Commonwealth Equity Services, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Commonwealth Equity Services, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Commonwealth Equity Services, LLC with notifications on news.